N30
08-26

$Novo-Nordisk A/S(NVO)$ Novo Nordisk dominates a booming industry. Even after the big run up, strong demand for its therapies could keep it a solid long-term play.

Novo Nordisk Heavily Undervalued, Market Outlook Upbeat
Novo Nordisk is seriously undervalued, with revenue and profit growth exceeding 20%, occupying a dominant position in the weight loss market, a 60% drop in stock price may be excessive, and the industry has huge growth potential
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
1
4